论文部分内容阅读
目的探讨中等剂量二丙酸氯地米松短疗程吸入治疗慢性阻塞性肺疾病稳定期患者的疗效。方法按照随机、对照、单盲的设计,将44例稳定期慢性阻塞性肺疾病患者分2组,观察组给予二丙酸氯地米松(800μg/d)与对照组给予安慰剂吸入治疗6周,观察治疗前后测定肺功能第1秒用力呼气量、用力肺活量,并记录临床症状评分及生活质量评分。结果观察组21例,临床症状改善,治疗前症状评分为(5.1±0.5)分,治疗后为(4.6±0.4)分(P<0.05);第1秒用力呼气量治疗前为(1.79±0.02)L,治疗后为(2.16±0.03)L(P<0.01);用力肺活量治疗前为(2.20±0.02)L,治疗后为(2.50±0.03)L(P<0.05),呼吸功能提高显著。对照组19例,治疗前后各项指标均无显著性差异(P>0.05)。结论短期二丙酸氯地米松吸入治疗稳定期慢性阻塞性肺疾病患者可缓解临床症状,提高肺功能和生活质量。
Objective To investigate the effect of middling dose of beclomethasone dipropionate short-course inhalation in patients with stable chronic obstructive pulmonary disease. Methods According to a randomized, controlled and single-blind design, 44 stable chronic obstructive pulmonary disease patients were divided into two groups. The observation group was treated with beclomethasone dipropionate (800 μg / d) and the control group with placebo inhalation for 6 weeks The forced expiratory volume and forced vital capacity of the first second of lung function were measured before and after treatment. The clinical symptom score and quality of life score were recorded. Results The observation group was improved in 21 cases, with symptom score of (5.1 ± 0.5) points before treatment and (4.6 ± 0.4) points after treatment (P <0.05). The first second forced expiratory volume was (1.79 ± (2.20 ± 0.02) L before treatment and (2.50 ± 0.03) L after treatment (P <0.05), and the respiratory function increased significantly (P <0.01) . In the control group, there were no significant differences in all the indexes before and after treatment (P> 0.05). Conclusion Short-term exposure to clomipramine dipropionate in patients with stable chronic obstructive pulmonary disease can relieve clinical symptoms and improve lung function and quality of life.